ALX ONCOLOGY HOLDINGS INC Increase (Decrease) in Other Accrued Liabilities
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Increase (Decrease) in Other Accrued Liabilities of -$1.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other accrued liabilities for the quarter ending 2026-06-30 was $1.36M.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other accrued liabilities for the quarter ending 2026-03-31 was -$3.01M.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other accrued liabilities for the quarter ending 2025-12-31 was -$2.15M.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other accrued liabilities for the quarter ending 2025-09-30 was $6.17M.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other accrued liabilities for fiscal 2025 was $2.00M.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other accrued liabilities for fiscal 2024 was -$12.62M, a 212.47% decline from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other accrued liabilities for fiscal 2023 was $11.22M, a 59.73% increase from fiscal 2022.
- ALX ONCOLOGY HOLDINGS INC increase (decrease) in other accrued liabilities for fiscal 2022 was $7.03M, a 112.55% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 9 month | Increase (Decrease) in Other Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.65M 10-Q · filed 2026-08-06 | -$3.80M derived: sum of 3 quarters · filed 2026-08-06 | $2.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$3.01M 10-Q · filed 2026-05-08 | -$5.16M derived: sum of 2 quarters · filed 2026-05-08 | $1.01M derived: sum of 3 quarters · filed 2026-05-08 | -$913.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $4.02M derived: sum of 2 quarters · filed 2026-03-09 | $2.10M derived: sum of 3 quarters · filed 2026-08-06 | $2.00M 10-K · filed 2026-03-09 |
| 2025-09-30 | $6.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $4.25M derived: sum of 2 quarters · filed 2026-08-06 | $4.15M 10-Q · filed 2025-11-07 | -$6.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.02M 10-Q · filed 2026-08-06 | -$12.91M derived: sum of 3 quarters · filed 2026-08-06 | -$18.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$97.00K 10-Q · filed 2026-05-08 | -$10.99M derived: sum of 2 quarters · filed 2026-05-08 | -$16.38M derived: sum of 3 quarters · filed 2026-05-08 | -$11.64M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$10.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$16.28M derived: sum of 2 quarters · filed 2026-03-09 | -$11.54M derived: sum of 3 quarters · filed 2026-03-09 | -$12.62M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$5.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$651.00K derived: sum of 2 quarters · filed 2025-11-07 | -$1.73M 10-Q · filed 2025-11-07 | $3.00M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $4.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $3.66M 10-Q · filed 2025-08-12 | $8.39M derived: sum of 3 quarters · filed 2026-03-09 | $16.69M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | -$1.08M 10-Q · filed 2025-05-08 | $3.65M derived: sum of 2 quarters · filed 2026-03-09 | $11.95M derived: sum of 3 quarters · filed 2026-03-09 | $15.70M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | $4.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $13.03M derived: sum of 2 quarters · filed 2026-03-09 | $16.77M derived: sum of 3 quarters · filed 2026-03-09 | $11.22M 10-K · filed 2026-03-09 |
| 2023-09-30 | $8.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $12.04M derived: sum of 2 quarters · filed 2024-11-07 | $6.49M 10-Q · filed 2024-11-07 | $7.11M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $3.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$1.80M 10-Q · filed 2024-08-12 | -$1.19M derived: sum of 3 quarters · filed 2025-03-06 | $2.46M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$5.55M 10-Q · filed 2024-05-09 | -$4.94M derived: sum of 2 quarters · filed 2025-03-06 | -$1.28M derived: sum of 3 quarters · filed 2025-03-06 | $2.78M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $615.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $4.27M derived: sum of 2 quarters · filed 2025-03-06 | $8.33M derived: sum of 3 quarters · filed 2025-03-06 | $7.03M 10-K · filed 2025-03-06 |
| 2022-09-30 | $3.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $7.72M derived: sum of 2 quarters · filed 2023-11-13 | $6.41M 10-Q · filed 2023-11-13 | $7.38M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-06-30 | $4.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.76M 10-Q · filed 2023-08-10 | $3.73M derived: sum of 3 quarters · filed 2024-03-07 | $4.86M derived: sum of 4 quarters · filed 2024-03-07 |
| 2022-03-31 | -$1.30M 10-Q · filed 2023-05-11 | -$331.00K derived: sum of 2 quarters · filed 2024-03-07 | $792.00K derived: sum of 3 quarters · filed 2024-03-07 | $1.42M derived: sum of 4 quarters · filed 2024-03-07 |
| 2021-12-31 | $973.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $2.10M derived: sum of 2 quarters · filed 2024-03-07 | $2.72M derived: sum of 3 quarters · filed 2024-03-07 | $3.31M 10-K · filed 2024-03-07 |
| 2021-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.75M derived: sum of 2 quarters · filed 2022-11-08 | $2.33M 10-Q · filed 2022-11-08 | $5.32M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-06-30 | $625.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $1.21M 10-Q · filed 2022-08-08 | $4.20M derived: sum of 3 quarters · filed 2023-03-09 | $5.09M derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-03-31 | $585.00K 10-Q · filed 2022-05-09 | $3.57M derived: sum of 2 quarters · filed 2023-03-09 | $4.47M derived: sum of 3 quarters · filed 2023-03-09 | $6.18M derived: sum of 4 quarters · filed 2023-03-09 |
| 2020-12-31 | $2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $3.88M derived: sum of 2 quarters · filed 2023-03-09 | $5.60M derived: sum of 3 quarters · filed 2023-03-09 | $4.98M 10-K · filed 2023-03-09 |
| 2020-09-30 | $895.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $2.61M derived: sum of 2 quarters · filed 2021-11-12 | $2.00M 10-Q · filed 2021-11-12 | $2.42M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $1.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.10M 10-Q · filed 2021-08-12 | $1.52M derived: sum of 3 quarters · filed 2022-02-28 | $1.72M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$614.00K 10-Q · filed 2021-05-17 | -$189.00K derived: sum of 2 quarters · filed 2022-02-28 | $3.00K derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | $425.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $617.00K derived: sum of 2 quarters · filed 2022-02-28 | $134.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $192.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$291.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | -$483.00K 10-Q · filed 2020-08-27 | |||
| 2018-12-31 | $9.00K 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |